September 24th 2020
Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.
September 22nd 2020
Alexander N. Shoushtari, MD, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.
September 19th 2020
Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.
Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.
September 18th 2020
The PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression.
Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.
September 17th 2020
In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.
September 16th 2020
Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma.
September 15th 2020
Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.
September 10th 2020
Omid Hamid, MD, discusses emerging biomarkers in melanoma, data supporting their efficacy and their potential for use in clinical practice, and future directions for research.
